Key Takeaways
- The only completed human RCT program used oral AOD 9604 at doses from 1 mg to 9 mg/day; the 1 mg oral dose showed the most favorable signal in a 12-week trial (n=300, Metabolic Pharmaceuticals).
- Subcutaneous research protocols most commonly cite 250-500 mcg per day as a flat dose, but no published human RCT has validated subcutaneous dose-ranging specifically.
- A standard 5 mg vial reconstituted in 2 mL bacteriostatic water yields 2500 mcg/mL; a 250 mcg dose equals exactly 10 units on a U-100 insulin syringe.
- AOD 9604 has GRAS status for food use (FDA GRN 000548, 2014) but was removed from FDA's 503A compounding bulk substances list in 2023, restricting legal compounded availability in the U.S.
- In all human trial data available, AOD 9604 did not significantly elevate IGF-1, fasting glucose, or insulin, which distinguishes it mechanistically from exogenous HGH, though human efficacy data for meaningful fat loss remains weak.
What Is the Standard AOD 9604 Dosage?
Table of Contents
- What Is AOD 9604 and What Does It Do?
- Evidence Ledger: What the Data Actually Supports
- Mechanism With Numbers: How AOD 9604 Targets Fat Cells
- AOD 9604 Dosage Chart
- AOD 9604 5mg Reconstitution: Step-by-Step Math
- What Most Pages Get Wrong About AOD 9604 Dosage
- Injection Protocol: Timing, Site, and Cycle Length
- Honest Head-to-Head: AOD 9604 vs. Real Alternatives
- Label and COA Literacy: How to Judge What You Are Buying
- Side Effects and Safety Data
- FAQ
- Sources
What Is AOD 9604 and What Does It Do?
AOD 9604 (also written AOD9604 or AOD-9604) is a synthetic peptide fragment corresponding to amino acids 177-191 of the C-terminal region of human growth hormone (hGH), with an added tyrosine residue at the N-terminus. "AOD" stands for Anti-Obesity Drug. It was developed by Metabolic Pharmaceuticals (Melbourne, Australia) with the goal of isolating the lipolytic activity of hGH while eliminating the diabetogenic and proliferative effects associated with IGF-1 elevation.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →The peptide binds to the beta-3 adrenergic receptor pathway involved in adipocyte lipolysis, stimulating fat breakdown without acting on the classical GH receptor in a way that drives IGF-1 production. That mechanistic distinction is real; whether it translates to clinically meaningful fat loss in humans is a separate, weaker question.
Evidence Ledger: What the Data Actually Supports
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| AOD 9604 stimulates lipolysis in fat cells | In vitro cell studies; animal studies (obese mice) | Positive | Moderate |
| AOD 9604 does not significantly raise IGF-1 or blood glucose | Human clinical trial data (Metabolic Pharmaceuticals, oral doses) | Neutral (no significant change) | Moderate |
| AOD 9604 produces meaningful fat loss in obese humans | Human RCTs (oral formulation); results non-significant vs. placebo in key trials | Weak / inconclusive | Low |
| 250-500 mcg subcutaneous is an effective dose range | Convention; extrapolated from oral trial doses; no human SQ dose-ranging RCT | Unknown direction | Very Low |
| AOD 9604 is safe at doses up to 9 mg/day orally over 24 weeks | Human clinical trials (Metabolic Pharmaceuticals) | No serious adverse events reported | Moderate |
| AOD 9604 supports cartilage/joint repair | In vitro and animal studies only | Positive in animal models | Very Low (no human data) |
| Fasted morning injection optimizes effect | Mechanistic reasoning; no human timing comparison trial | Plausible | Very Low |
Mechanism With Numbers: How AOD 9604 Targets Fat Cells
The 15-amino-acid sequence of AOD 9604 (Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe) retains the disulfide bond between Cys182 and Cys189 of native hGH, which is necessary for the compound's biological activity. Structural studies show this region interacts with fat cell receptors differently than the N-terminal domain of hGH that drives GH receptor signaling and downstream IGF-1 secretion.
In rodent studies (Heffernan et al., published in work associated with Metabolic Pharmaceuticals), AOD 9604 administered to obese mice reduced body weight and fat mass, and increased lipolysis markers. The proposed receptor pathway involves beta-3 adrenergic receptors on adipocytes, stimulating cAMP-mediated activation of hormone-sensitive lipase (HSL), which catalyzes triglyceride breakdown into free fatty acids and glycerol.
What this mechanism does NOT prove: Demonstrating lipolysis in adipocytes in cell culture, or weight reduction in diet-induced obese mice, does not predict the magnitude or even direction of effect in humans with normal or high caloric intake. Liberated fatty acids are re-esterified if caloric surplus continues. The human trials, which are the only real test, showed modest and often statistically non-significant results.
AOD 9604 Dosage Chart
| Context | Route | Daily Dose | Frequency | Evidence Basis |
|---|---|---|---|---|
| Metabolic Pharm. Phase 2b trial (12 weeks, n=300) | Oral (proprietary) | 1 mg (1000 mcg) | Once daily | Human RCT (most favorable signal) |
| Metabolic Pharm. dose-ranging trials | Oral (proprietary) | 250 mcg to 9 mg | Once daily | Human RCT (multiple arms) |
| Research SQ low dose | Subcutaneous injection | 250 mcg | Once daily | Research convention only |
| Research SQ standard dose | Subcutaneous injection | 500 mcg | Once daily | Research convention only |
| Research SQ higher dose | Subcutaneous injection | 1000 mcg (1 mg) | Once daily | Extrapolated from oral 1 mg trial; no SQ equivalence data |
Body weight-based dosing: No published human trial has established weight-based dosing for AOD 9604. Clinical trials used flat daily doses. Pages citing "mcg per kg" dosing for subcutaneous AOD 9604 are applying a convention not supported by published trial data.
AOD 9604 5mg Reconstitution: Step-by-Step Math
Supplies needed
- 5 mg lyophilized AOD 9604 vial
- Bacteriostatic water for injection (BAC water, 0.9% benzyl alcohol)
- 2 mL or 3 mL syringe for reconstitution
- U-100 insulin syringes for dosing (29-31 gauge, 0.5 inch recommended)
- Alcohol wipes
Reconstitution math: 5 mg vial with 2 mL BAC water
| Vial size | BAC water added | Concentration | Dose | Volume to draw | Units on U-100 syringe |
|---|---|---|---|---|---|
| 5 mg (5000 mcg) | 2.0 mL | 2500 mcg/mL | 250 mcg | 0.10 mL | 10 units |
| 5 mg (5000 mcg) | 2.0 mL | 2500 mcg/mL | 500 mcg | 0.20 mL | 20 units |
| 5 mg (5000 mcg) | 2.0 mL | 2500 mcg/mL | 1000 mcg | 0.40 mL | 40 units |
Step-by-step protocol
- Wipe both vial tops with alcohol. Allow to dry 30 seconds.
- Draw the desired volume of BAC water into the reconstitution syringe.
- Insert the needle into the peptide vial at an angle and direct the stream of water down the glass wall, not directly onto the lyophilized cake. This prevents protein denaturation from mechanical shear.
- Withdraw the needle. Gently swirl the vial for 30-60 seconds. Do not shake, vortex, or invert repeatedly; physical agitation can cause peptide aggregation.
- The solution should be clear and colorless. Any particulate matter or color change indicates a problem with the peptide or water source. Do not use.
- Label the vial with the date and concentration. Store at 2-8°C (standard refrigerator). Protect from light.
Why bacteriostatic water, not sterile water?
Bacteriostatic water contains 0.9% benzyl alcohol, a preservative that inhibits microbial growth and extends the usable life of the reconstituted vial to approximately 28 days refrigerated. Sterile water for injection contains no preservative; once opened, it is considered suitable for single use only. Using sterile water for multi-dose vials increases contamination risk meaningfully.
What Most Pages Get Wrong About AOD 9604 Dosage
1. Conflating oral trial doses with subcutaneous doses
The 1 mg dose that showed the best signal in human trials was delivered in a proprietary oral formulation with a specific delivery system. Oral peptide bioavailability is profoundly affected by gastrointestinal proteases. Without that delivery system, unformulated oral AOD 9604 is largely degraded before absorption. Most dosing pages copy "1 mg/day" from the trial without acknowledging this distinction. Whether 500 mcg subcutaneously delivers equivalent systemic exposure to 1 mg orally in a proprietary formulation is unknown because that bioequivalence study has not been published.
2. Presenting weight-based dosing as clinical fact
Numerous pages cite dosing tables in "mcg/kg of body weight." No human trial has established weight-based dosing for AOD 9604. These tables are conventions borrowed from GH dosing frameworks and applied without validation. They may be reasonable guesses; they are not clinical data.
3. Overstating what GRAS means
AOD 9604 received FDA GRAS determination (GRN 000548) for use as a food ingredient. GRAS relates to a specific context (food ingredient at the proposed use level) and does not constitute approval as a drug, a therapeutic agent, or a compounded medication. Several commercial pages cite GRAS as evidence of safety for injection, which misrepresents the regulatory designation.
4. Ignoring the 2023 FDA compounding change
In 2023, the FDA finalized a decision removing AOD 9604 from the list of bulk drug substances that can be used in compounded preparations under Section 503A of the FD&C Act. Pages written before this change, or pages that have not been updated, may present AOD 9604 as readily available through compounding pharmacies, which is no longer legally accurate in the United States.
Injection Protocol: Timing, Site, and Cycle Length
Injection timing
Research protocols typically specify morning administration in a fasted state, or 30 minutes before exercise. The rationale: insulin inhibits lipolysis, and AOD 9604's proposed mechanism depends on activating the same beta-adrenergic/cAMP lipolytic pathway. Injecting in a high-insulin environment (postprandial) is mechanistically unfavorable. This reasoning is sound, but no human trial has compared morning fasted vs. postprandial timing directly.
Injection sites
Subcutaneous injection into abdominal fat (at least 2 inches from the navel), outer thigh, or lateral hip. Rotate sites to avoid lipodystrophy. The 29-31 gauge, 0.5-inch needle is sufficient for most subcutaneous sites.
Cycle length
Human clinical trials ran 12-24 weeks. Research community protocols commonly reference 12-16 week cycles. There are no published long-term safety data beyond the 24-week trial window, and no data on tolerance development. Off-cycle periods are convention, not evidence-based requirements.
Honest Head-to-Head: AOD 9604 vs. Real Alternatives
| Comparison | AOD 9604 | Competitor | Winner on this dimension |
|---|---|---|---|
| Human RCT evidence for fat loss | Multiple trials; results non-significant vs. placebo in published data | Semaglutide: ~15% body weight reduction in STEP 1 (Wilding et al., NEJM 2021, n=1961) | Semaglutide by a wide margin |
| IGF-1 and glucose safety profile | No significant IGF-1 or glucose elevation in trials | Exogenous HGH: elevates IGF-1, can cause insulin resistance, acromegaly risk | AOD 9604 |
| Regulatory clarity | Not FDA-approved; removed from 503A compounding list (2023) | Tirzepatide (Zepbound): FDA-approved for obesity | Tirzepatide |
| Anabolic/proliferative side effect risk | Low based on available data; does not drive GH receptor IGF-1 axis | CJC-1295 / Ipamorelin: elevate GH and IGF-1 | AOD 9604 (if safety matters most) |
| Evidence for joint/cartilage support | In vitro and animal data only | BPC-157: also largely animal data; similar evidence level | Tie (both very low human evidence) |
| Cost per month | Research peptide: relatively low per vial | Semaglutide: high without insurance; tirzepatide similar | AOD 9604 on cost alone |
Label and COA Literacy: How to Judge What You Are Buying
What a legitimate COA should include
- Purity by HPLC: Look for greater than 98% purity by high-performance liquid chromatography. Values below 95% indicate significant impurity burden.
- Molecular weight confirmation: AOD 9604 has a molecular weight of approximately 1817 Da (as the free acid). Mass spectrometry (MS) confirmation should show the correct molecular ion. A COA without MS is incomplete.
- Sequence verification: The correct sequence is Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe with a disulfide bridge. Some suppliers sell truncated or incorrect sequences that will not have the same activity.
- Endotoxin testing: For research use involving injection, bacterial endotoxin testing (LAL test) should be present. High endotoxin content causes fever and inflammatory reactions at the injection site.
- Sterility testing: Confirms absence of viable microorganisms. Not always present on research-grade COAs but is a meaningful quality marker.
What a degraded product looks like
Intact lyophilized AOD 9604 is a white to off-white powder. A properly reconstituted solution is clear and colorless. Warning signs of degradation or contamination: yellow or brown discoloration of the powder or reconstituted solution, visible particulates that do not dissolve, cloudy solution (indicates aggregation or contamination), or an unusual odor. Do not use a vial showing any of these signs.
Stability considerations
Peptide bonds and disulfide bridges are susceptible to degradation from heat, repeated freeze-thaw cycles, exposure to light (UV), and extreme pH. There are no published stability kinetics specific to AOD 9604. General peptide chemistry predicts that lyophilized powder stored below -20°C in a sealed, desiccated vial has stability measured in months to years, while reconstituted peptide with bacteriostatic water stored at 2-8°C degrades over weeks. Avoid storing reconstituted peptide at room temperature for extended periods.
Side Effects and Safety Data
In the Metabolic Pharmaceuticals clinical trial program, AOD 9604 was administered to human subjects at doses ranging from 250 mcg to 9 mg per day orally for up to 24 weeks. No serious adverse events were attributed to the compound. The safety profile was one of the compound's primary selling points compared to full-length GH therapy.
For subcutaneous injection, the expected and commonly reported effects include injection site reactions: mild redness, swelling, and transient discomfort at the injection site. These are standard for any subcutaneous peptide injection and typically resolve within hours. Rotating injection sites reduces the frequency and severity.
What is not known: Long-term safety beyond 24 weeks in humans has not been published. The safety profile established in oral trials does not automatically apply to subcutaneous administration, which bypasses gastrointestinal processing and may produce different pharmacokinetic exposure. No published pharmacokinetic study has characterized the half-life, Tmax, or Cmax of subcutaneously administered AOD 9604 in humans.
FAQ
What is the standard AOD 9604 dosage for fat loss?
The dose used in human clinical trials by Metabolic Pharmaceuticals was 1 mg (1000 mcg) per day orally. Subcutaneous injection protocols in research settings have used 250-500 mcg per day, typically administered once daily in a fasted state. No human RCT has established a dose-response curve for subcutaneous use specifically.
How do I reconstitute a 5mg vial of AOD 9604?
Add 2 mL of bacteriostatic water to a 5mg vial. This yields a concentration of 2500 mcg per mL. For a 250 mcg dose, draw 0.10 mL (10 units on a 100-unit insulin syringe). For a 500 mcg dose, draw 0.20 mL (20 units). Always inject the water slowly down the vial wall and swirl gently; do not shake.
How many units on an insulin syringe is 250 mcg of AOD 9604?
With a standard 5mg/2mL reconstitution (2500 mcg/mL), a 250 mcg dose equals 0.10 mL, which is 10 units on a 100-unit (U-100) insulin syringe. Always verify by recalculating from your own reconstitution volume.
When is the best time to inject AOD 9604?
Most research protocols administer AOD 9604 in the morning in a fasted state or 30 minutes before exercise. The rationale is that insulin inhibits the lipolytic pathway AOD 9604 is proposed to activate. This timing is mechanistically plausible but has not been confirmed by a human timing-comparison trial.
Does AOD 9604 raise IGF-1 or blood sugar?
Available human trial data from Metabolic Pharmaceuticals showed no significant change in fasting glucose, insulin, or IGF-1 at doses up to 9 mg/day orally. This is one of the compound's key differentiators from full-length growth hormone, but is based on data from the proprietary oral formulation with limited independent replication.
How long does a reconstituted vial of AOD 9604 last?
Reconstituted peptide vials prepared with bacteriostatic water are generally considered stable for up to 28 days when refrigerated at 2-8°C and protected from light. Lyophilized powder vials should be kept refrigerated or frozen before reconstitution. No published stability kinetics are available specifically for AOD 9604.
What does AOD stand for in AOD 9604?
AOD stands for Anti-Obesity Drug. The compound is a synthetic peptide fragment corresponding to amino acids 177-191 of the C-terminal region of human growth hormone, modified with an added tyrosine residue at the N-terminus.
Is AOD 9604 approved by the FDA?
No. AOD 9604 is not FDA-approved for any indication. It received GRAS determination for use as a food ingredient in 2014 (GRN 000548). The FDA removed AOD 9604 from the bulk substances list for 503A compounding in 2023, restricting its use in compounded preparations in the United States.
How does AOD 9604 compare to semaglutide for fat loss?
Semaglutide (Wegovy) has Phase 3 RCT data showing mean body weight reductions of roughly 15% over 68 weeks (STEP 1 trial, Wilding et al., NEJM 2021, n=1961). AOD 9604's human trial results were statistically non-significant for fat loss in key trials. AOD 9604 does not have remotely comparable human efficacy evidence.
What are the side effects of AOD 9604?
In clinical trials, AOD 9604 appeared well-tolerated with no serious adverse events at doses up to 9 mg/day orally over 24 weeks. Injection-site reactions (redness, mild swelling) are expected with subcutaneous administration. Long-term safety data beyond 6 months in humans is not available.
Can AOD 9604 be taken orally instead of injecting?
Human clinical trials used a proprietary oral delivery system. Unformulated oral peptide has very poor bioavailability due to gastrointestinal protease degradation. No published bioequivalence data compares unformulated oral to subcutaneous AOD 9604 in humans.
What is the AOD 9604 dosage chart by body weight?
No published human RCT has established weight-based dosing for AOD 9604. Clinical trials used flat daily doses. Research community protocols reference 250-500 mcg/day as a flat dose regardless of body weight, but